Abstract 1595
Economic impact of the Secondary Progressive Multiple Sclerosis in Spain: Interim analysis of the DISCOVER study
Type: Oral Presentation
Keyword: Patient-Reported Outcomes and Quality of Life
Authors: C. Oreja-Guevara1, J. Río2, J.R. Ara Callizo3, M.A. Hernández Pérez4, J. Gracia Gil5, L. Ramió I Torrenta6, B. Pilo De La Fuente7, A.M. Alonso Torres8, S. Martínez-Yélamos9, F. Gascón Giménez10, S. Eichau Madueño11, B. Casanova-Estruch12, M.L. Martínez Ginés13, M.L. Aguado Valcárcel14, J.E. Martínez Rodríguez15, A.M. López Real16, C. López De Silanes17, V. González Quintanilla18, Y. El Berdei Montero19, A. Labiano20, M. Garcés Redondo21, L. Costa-Frossard22, J.A. García Merino23, F. Castellanos Pinedo24, C. Muñoz Fernández25, V. Mecha-Lallana26, T. Castillo-Trivino27, A. Rodríguez-Antiedad28, J. Peña Martínez29, J.M. Prieto González30, D.M. Solar Sánchez31, I. Pérez Molina32, E. Agüera Morales33, N. Herrera Varo34, J. Meca-Lallana35; 1Hospital Universitario Clínico San Carlos/Madrid/Spain, 2CEMCAT, Hospital Universitario Vall d’Hebrón/Barcelona/Spain, 3Hospital Universitario Miguel Servet/Zaragoza/Spain, 4Hospital Universitario Nuestra Señora de la Candelaria/Santa Cruz De Tenerife/Spain, 5Complejo Hospitalario Universitario de Albacete/Albacete/Spain, 6Hospital Universitario de Girona Dr. Josep Trueta/Girona/Spain, 7Hospital Universitario de Getafe/Madrid/Spain, 8Hospital Regional Universitario Carlos Haya/Málaga/Spain, 9Hospital Universitario de Bellvitge/L’Hospitalet De Llobregat-Barcelona/Spain, 10Hospital Clínico de Valencia/Valencia/Spain, 11Hospital Universitario Virgen Macarena/Sevilla/Spain, 12Hospital Universitari i Politècnic La Fe/Valencia/Spain, 13Hospital Gregorio Marañón/Madrid/Spain, 14Hospital Álvaro Cunqueiro/Vigo/Spain, 15Hospital del Mar/Barcelona/Spain, 16Complejo Hospitalario Universitario A Coruña/A Coruña/Spain, 17Hospital Universitario de Torejón/Madrid/Spain, 18Hospital Universitario Marqués de Valdecilla/Cantabria/Spain, 19Hospital Universitario de Salamanca/Salamanca/Spain, 20Hospital Universitario 12 de Octubre/Madrid/Spain, 21Hospital Clínico Universitario Lozano Blesa/Zaragoza/Spain, 22Hospital Universitario Ramón y Cajal/Madrid/Spain, 23Hospital Universitario Puerta de Hierro/Madrid/Spain, 24Hospital Virgen del Puerto Plasencia/Cáceres/Spain, 25Hospital Universitario Torrecárdenas/Almería/Spain, 26Hospital Universitario de La Princesa/Madrid/Spain, 27Hospital Universitario Donostia/San Sebastián/Spain, 28Hospital Universitario de Cruces/Barakaldo/Spain, 29Hospital Universitario San Agustín/Asturias/Spain, 30Hospital Clínico Universitario de Santiago/Santiago De Compostela/Spain, 31Hospital Universitario de Cabueñes/Gijón/Spain, 32Hospital Virgen de la Salud/Toledo/Spain, 33Hospital Universitario Reina Sofia/Córdoba/Spain, 34Hospital Universitario de Burgos/Burgos/Spain, 35Hospital Clínico Universitario Virgen de la Arrixaca/Murcia/Spain

Background
Multiple Sclerosis (MS) is a chronic, inflammatory, autoimmune, neurodegenerative disease. Around 19% of treated patients with relapsing-remitting MS progress to Secondary Progressive MS (SPMS) 15 years after disease onset, representing the most severe stage of the disease. MS symptoms lead to a general disability, impacting the quality of life of patients and also being related with an important economic burden on the National Health System, the patients, their caregivers and the whole society.

Objectives
There are limited published data on the economic impact of SPMS. The main objective of the study was to estimate the economic impact of SPMS in Spain.
Methods
DISCOVER (CBAF312AES01) is an observational, non-interventional, cross-sectional, retrospective and multicenter study, including 297 SPMS patients ≥18 years treated and monitored according to routine clinical practice in Spain in 34 public hospitals. All data was collected in one single visit. Primary endpoint: total annual cost per patient, including direct healthcare and non-healthcare costs and indirect costs. Interim results from 99 patients are presented.

Results
62.6% females; mean (SD) age 53.1 (9.3) years; 40.4% with higher education; 86.9% living with a relative. Mean (SD) time since first MS diagnosis was 17.5 (8.9) years and since progression to SPMS 5.2 (4.3) years. At diagnosis, mean (SD) EDSS was 2.0 (1.1), being 5.0 (1.1) at the time of progression and 5.9 (0.8) at the study visit, 47.5% patients reaching EDSS>6. 12.8% of patients presented relapses between 12-24 months before the study. According to EQ-5D-5L, mean (SD) utility (<1) was 0.48 (0.27) for patients with Gd+ lesions and/or relapses 2 years before. According to EQ-5D-5L, mean (SD) utility (<1) for patients with cognitive impairment was 0.45 (0.29) vs 0.51 (0.21) for those without it. Mean (SD) utility for Spanish general population was 0.897 (0.21). EDSS score showed a significative effect (P=0.0074) on the economic burden of the disease, with total costs increasing from 14,546€ (EDSS 4-4.5) to 21,918€ (EDSS 5-5.5) and 26,832€ (EDSS=6). Costs related to patients with EDSS=6 from the societal, patient and healthcare system were 6,441€, 8,450€ and 11,941€, respectively.

Conclusions
Interim results of the DISCOVER study revealed a significant economic impact of MS progression, highlighting the importance of implementing therapeutic strategies specific to the SPMS patient within the early stages of progression.